1. Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study
2. Phase I dose escalation and expansion study of golidocitinib, a highly selective JAK1 inhibitor, in relapsed or refractory peripheral T-cell lymphomas
3. FDA fast track designation for DZD4205 (golidocitinib) for the treatment of refractory or relapsed peripheral T‐cell lymphoma. News release;Dizal Pharmaceutical receives U.S.;Dizal Pharmaceutical,2022
4. Dizal Pharmaceutical 2023 Dizal announces China CDE acceptance of new drug application for golidocitinib for relapsed or refractory PTCL. News release